Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors

SIMPLE SUMMARY: Focal cryoablation is an FDA-approved minimally-invasive treatment for certain kidney, colon, lung, breast, and prostate cancers. However, it is difficult to ensure complete tumor destruction after ablation, and therefore, tumor recurrence rates can be as high as 80%. In order to imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrabel, Maura R., Schulman, Jacob A., Gillam, Francis B., Mantooth, Siena M., Nguyen, Khue G., Zaharoff, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137033/
https://www.ncbi.nlm.nih.gov/pubmed/37190138
http://dx.doi.org/10.3390/cancers15082210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137033/
https://www.ncbi.nlm.nih.gov/pubmed/37190138
http://dx.doi.org/10.3390/cancers15082210

Ejemplares similares